1137916-97-2

MK-0941 mesylate is a glucokinase activator (GKA) potentially for the treatment of type 2 diabetes. MK-0941 led to improvements in glycemic control that were not sustained. MK-0941 was associated with an increased incidence of hypoglycemia and elevations in triglycerides and blood.